EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension

Chrysoula Boutari iD, Fotios Siskos iD

Life · 16.03.2023 · 13 (3) · 806

DOI: 10.3390/life13030806 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Life, online erschienen am 16.03.2023. Verfasst von Chrysoula Boutari und 1 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration General Hospital, 54642 Thessalon…. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resistant hypertension (RH) is defined as the failure to achieve blood pressure control despite using triple combination therapy with a renin-angiotensin system inhibitor (RAS-i), a calcium antagonist, and a diuretic. The endothelin (ET) system is implicated in the regulation of vascular tone, primarily through vasoconstriction, intervenes in cardiac contractility with inotropic effects, and contributes to water and sodium renal reabsorption. ET inhibitors, currently approved for the treatment of pulmonary hypertension, seem to be also useful for essential hypertension and RH as well. Studies into the development of new dual ET inhibitors, which inhibit both type A and B ET (ETA and ETB) receptors, present initial results of managing RH. Aprocitentan (ACT-132577) is a novel, orally active and well tolerated dual ET receptor antagonist, which has been examined in several experimental studies and clinical trials with promising results for RH control. The recent publication of the large PRECISION study in The Lancet journal provides further reassurance regarding the efficacy and safety of aprocitentan for RH, with the aim of overcoming unmet needs in the management of this difficult group of patients.

Schlagwörter

Stichwörter der Autor:innen

aprocitentancardiovascular diseasesendothelin receptor inhibitorsendothelin systemresistant hypertension

Autor:innen und Institutionen

  • 2nd Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, Hippokration General Hospital, 54642 Thessaloniki, Greece.

ORCID-Profile: Chrysoula Boutari, Fotios Siskos

Zitieren

APA

Boutari, C., & Siskos, F. (2023). Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension. Life, 13(3), 806. https://doi.org/10.3390/life13030806

Vancouver

Boutari C, Siskos F. Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension. Life. 2023;13(3):806. doi:10.3390/life13030806

BibTeX
@article{Boutari2023,
  author = {Boutari, Chrysoula and Siskos, Fotios},
  title = {Novel Dual Endothelin Inhibitors in the Management of Resistant Hypertension},
  journal = {Life},
  year = {2023},
  volume = {13},
  number = {3},
  pages = {806},
  doi = {10.3390/life13030806}
}
Kostenlos starten →